Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 2/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | CPT1A | P50416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16498013 | 0.89 | CCNK (0.44) | FFAR2NPC1RAB9ATYRCCNK | |
| SCHEMBL1914994 | 0.86 | FFAR2 (0.48) | FFAR2FYNHASPINTYRCYP19A1 | |
| SCHEMBL16498003 | 0.86 | NPC1 (0.46) | NPC1RAB9ATYRMAPTVCP | |
| SCHEMBL16498184 | 0.86 | FFAR2 (0.43) | FFAR2FYNNPC1RAB9AHASPIN | |
| SCHEMBL16498186 | 0.86 | FFAR2 (0.43) | FFAR2FYNNPC1RAB9AHASPIN | |
| SCHEMBL1915039 | 0.85 | AR (0.48) | FFAR2FYNNPC1RAB9ACYP19A1 | |
| SCHEMBL16498043 | 0.84 | FFAR2 (0.41) | FFAR2FYNNPC1RAB9ATYR | |
| SCHEMBL16498375 | 0.84 | RAB9A (0.48) | NPC1RAB9ATYRMAPTVCP | |
| SCHEMBL16498495 | 0.83 | RAB9A (0.46) | NPC1RAB9ATYRMAPTVCP | |
| SCHEMBL1915236 | 0.82 | NPC1 (0.47) | FFAR2NPC1RAB9ATYRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102245574-A | Compounds, pharmaceutical compositions and methods for treating metabolic disorders | EUROSCREEN SA | 2011-11-16 | — | — | CN | disclosed |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | FFAR2 295/4885FYN 3212/4885NPC1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.